An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
NCT ID: NCT06503224
Last Updated: 2025-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
18 participants
INTERVENTIONAL
2024-04-09
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT07052565
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
NCT06420154
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT06775912
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-BCMA and CD19 CART
Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of Anti-BCMA and CD19 CART will be infused on day 0.
Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. At the time of signing the informed consent form, the age of 18 years old or above, both male and female.
3. Bone marrow hematopoietic function is satisfied: white blood cell count ≥3×10\^9/L; neutrophil count ≥1×10\^9/L (not receiving colony-stimulating factor within 2 weeks prior to screening); hemoglobin ≥60g/L.
4. Liver function fulfillment: ALT≤3×ULN; AST≤3×ULN; TBIL≤3×ULN.
5. Renal function fulfillment: creatinine clearance CrCl ≥ 60mL/min.
6. Coagulation function meets: international standard ratio INR \<1.5 times ULN, prothrombin time PT \<1.5 times ULN.
Patients with rheumatoid arthritis must also meet the following enrollment criteria:
1. Diagnosis of rheumatoid arthritis according to the 2010 ACR / EULAR diagnostic criteria.
2. Fulfillment of one of the following conditions: DAS28-ESR \>3.2 or CDAI \>10 at 3 months after use of a standard treatment regimen prior to screening; inability to taper hormones (prednisone) to less than 7.5 mg/day; and number of swollen joints and/or number of joints with tenderness ≥3. Standard treatment regimen is defined as the stable use of any of the following (alone or in combination): corticosteroids, nonsteroidal anti-inflammatory drugs ( NSAIDs) and csDMARDs, including methotrexate, leflunomide, hydroxychloroquine, salazosulfapyridine, elamodex, tretinoin, and paeonia lactiflora total, as well as biological agents (including TNF inhibitors, non-TNF inhibitors, and JAK inhibitors).
3. Stable treatment with 1 or 2 cs DMARD(s) prior to enrollment as follows: at least 12 weeks of methotrexate and at least 4 weeks of administration at a dose of 7.5-25 mg/week; at least 4 weeks of stable hydroxychloroquine doses of ≤400 mg/d; at least 4 weeks of stable oral salicylazosulfapyridine 1 to 3 g/d; at least 4 weeks of stable oral leflunomide 10-20 mg /d.
Patients with SLE will also be required to meet the following enrollment criteria:
1. Diagnosis of SLE according to the 2019 EULAR/ACR classification criteria for SLE.
2. A history of SLE for at least 6 months prior to screening, with the disease remaining active 2 months after the use of a standard treatment regimen prior to screening. Standard treatment regimen is defined as stable use of any of the following (alone or in combination): corticosteroids, antimalarials, nonsteroidal anti-inflammatory drugs (NSAIDs), and other immunosuppressive or biologic agents, including azathioprine, mertiomaxolide, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine, belimumab, rituximab, and tetracycline.
3. BILAG-2004 assessment of the presence of at least 1 grade A or 2 grade B organ scores.
4. Positive for at least one of the following antibodies: anti-nuclear antibody, anti-ds-DNA antibody, anti-Sm antibody.
5. SLEDAI-2000 score ≥ 8 during the screening period.
Patients with dry syndrome were also required to meet the following enrollment criteria:
1. Diagnosis of dry syndrome according to the 2002 International Classification Criteria for Primary Dry Syndrome or the 2016 ACR/EULAR classification criteria.
2. Diagnosis of pSS-TP with platelet count \<30 x 10\^9/L.
3. History of dry syndrome for at least 6 months prior to screening and disease still active 2 months after use of conventional treatment regimen prior to screening. Definition of conventional therapy:Use of glucocorticoids (above 1 mg/Kg/d) and cyclophosphamide, and any of the following immunomodulatory drugs for more than 6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, and cyclosporine, as well as biologics, such as rituximab, belimumab, and tetraciprazole.
Patients with systemic sclerosis were also required to meet the following enrollment criteria:
1. Diagnosis of systemic sclerosis according to the 2013 ACR classification criteria for systemic sclerosis.
2. Positive antinuclear antibodies at screening.
3. Presence of clear evidence of HRCT progression.
4. History of systemic sclerosis for at least 6 months prior to screening, and active disease 2 months after use of a conventional treatment regimen prior to screening. Definition of conventional therapy:Use of glucocorticoids (above 0.5 mg/Kg/d) and cyclophosphamide for more than 6 months, as well as any of the following immunomodulatory medications: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, and cyclosporine, as well as biologics, such as rituximab and belimumab.
Exclusion Criteria
2. Those suffering from relatively serious heart diseases such as angina pectoris, myocardial infarction, heart failure and arrhythmia.
3. History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation.
4. vaccination, B-cell targeted therapy within 4 weeks prior to screening.
5. History of any malignant disease.
6. Patients with end-stage renal failure.
7. Presence or suspected presence of uncontrolled fungal, bacterial, viral or other infections.
8. History of severe allergy to drugs used in clinical studies or raw materials of test drugs, such as cyclophosphamide, fludarabine, DMSO.
9. The patient is positive for HBV surface antigen, or HBV core antibody and positive for DNA by RT-PCR; positive for HCV antibody or positive for HIV antibody or positive for syphilis or positive for CMV DNA or positive for EBV DNA.
10. Females who are pregnant or breastfeeding or who plan to have a pregnancy within 2 years of return infusion of the test drug; partners of male patients who plan to become pregnant within 2 years of treatment with the test drug.
11. Evidence of active tuberculosis infection.
12. other circumstances assessed by the investigator as unsuitable for enrollment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of University of Science and Technology of China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
zhu chen, M.D
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of University of Science and Technology of China
xingbing wang, M.D
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of University of Science and Technology of China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hunan Siweikang Therapeutic Co.Ltd
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SWKCART24031101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.